JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB145056

SU 5416 (Semaxanib), VEGFR-2 inhibitor

Be the first to review this product! Submit a review

|

(3 Publications)

MW 238.28 Da, Purity >99%. Selective VEGFR-2 inhibitor. Adenine mimetic. Inhibits endothelial cell proliferation. Inhibits angiogenesis and shows antitumor effects in vivo. .

View Alternative Names

CD309, CD309 antigen, EC 2.7.10.1, FLK-1, FLK1, mouse, homolog of, FLT, FLT-4, FLT41, FRT, Fetal liver kinase 1, Flt-1, Fms related tyrosine kinase 1, Fms related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), Fms related tyrosine kinase 1 vascular endothelial growth factor/vascular permeability factor receptor, Fms related tyrosine kinase 4, Fms-like tyrosine kinase 1, Fms-like tyrosine kinase 4, KRD1, Kdr, Kinase insert domain receptor, Kinase insert domain receptor (a type III receptor tyrosine kinase), LMPH1A, Ly73, PCL, Protein-tyrosine kinase receptor flk-1, Soluble VEGF receptor 1 14, Soluble VEGFR1 variant 2, Soluble VEGFR1 variant 21, Soluble VEGFR3 variant 1, Soluble VEGFR3 variant 2, Soluble VEGFR3 variant 3, Tyrosine kinase growth factor receptor, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Tyrosine-protein kinase receptor FLT4, VEGFR, VEGFR-1, VEGFR-2, VEGFR-3, VGFR1_HUMAN, VGFR2_HUMAN, VGFR3_HUMAN, Vascular endothelial growth factor receptor 1, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, Vascular endothelial growth factor receptor 3 precursor, Vascular endothelial growth factor vascular permeability factor receptor, Vascular permeability factor receptor, Vascular permeability factor receptor 1, soluble VEGFR2

1 Images
Chemical Structure - SU 5416 (Semaxanib), VEGFR-2 inhibitor (AB145056)
  • Chemical Structure

Lab

Chemical Structure - SU 5416 (Semaxanib), VEGFR-2 inhibitor (AB145056)

2D chemical structure image of ab145056, SU 5416 (Semaxanib), VEGFR-2 inhibitor

Key facts

CAS number

194413-58-6

Purity

>99%

Form

Solid

form

Molecular weight

238.28 Da

Molecular formula

C<sub>1</sub><sub>5</sub>H<sub>1</sub><sub>4</sub>N<sub>2</sub>O

PubChem

5329098

Nature

Synthetic

Solubility

Soluble in ethanol to 10 mM

Soluble in DMSO to 100 mM

Biochemical name

Semaxanib

Biological description

Selective VEGFR-2 inhibitor. Adenine mimetic. Inhibits endothelial cell proliferation. Inhibits angiogenesis and shows antitumor effects in vivo.

Canonical smiles

CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C

Isomeric smiles

CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C

InChi

InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-

InChiKey

WUWDLXZGHZSWQZ-WQLSENKSSA-N

IUPAC Name

(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The VEGF receptors—VEGF Receptor 1 (Flt-1) VEGF Receptor 2 (KDR/Flk-1) and VEGF Receptor 3 (Flt-4)—are tyrosine kinase receptors that mediate vascular endothelial growth factor (VEGF) signaling. These receptors vary in molecular mass with VEGF Receptor 1 being approximately 180 kDa VEGF Receptor 2 about 200 - 210 kDa and VEGF Receptor 3 around 195 - 200 kDa. They are expressed on the surface of various cells primarily vascular endothelial cells where they regulate different functions related to angiogenesis and lymphangiogenesis.
Biological function summary

These receptors play roles in modulating vascular permeability endothelial cell proliferation and blood vessel formation. They are part of complexes that include ligands such as various VEGF isoforms. VEGF Receptor 2 is the principal mediator of VEGF-induced endothelial cell responses. VEGF Receptor 1 serves as a decoy receptor to modulate the availability of VEGF for VEGF Receptor 2 whilst VEGF Receptor 3 mainly regulates lymphatic endothelial cell functions.

Pathways

These receptors are central to the VEGF signaling pathway which plays a role in angiogenesis and vasculogenesis. The pathway involves a cascade where VEGF binding leads to receptor dimerization and phosphorylation of intracellular domains activating downstream pathways like the MAPK and PI3K/Akt pathways. These receptors interact with various proteins including growth factors and other signaling molecules to ensure proper vascular function and adaptation.

Dysregulation of VEGF receptor signaling is implicated in cancer and retinal diseases. Overexpression or aberrant activation of VEGF Receptor 2 in particular is associated with tumor-induced angiogenesis allowing tumors to grow their own blood supply. In eye diseases like age-related macular degeneration improper VEGF signaling contributes to abnormal blood vessel formation. Other proteins such as neuropilins modulate these interactions serving as co-receptors to alter binding affinity and signaling output in disease contexts.

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in pharmacology 13:968124 PubMed36091747

2022

Honokiol improves depression-like behaviors in rats by HIF-1α- VEGF signaling pathway activation.

Applications

Unspecified application

Species

Unspecified reactive species

Xiao-Xu Fan,Wen-Yan Sun,Yu Li,Qin Tang,Li-Na Li,Xue Yu,Shu-Yan Wang,Ang-Ran Fan,Xiang-Qing Xu,Hong-Sheng Chang

Nature communications 10:1442 PubMed30926814

2019

Excessive mechanical loading promotes osteoarthritis through the gremlin-1-NF-κB pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Song Ho Chang,Daisuke Mori,Hiroshi Kobayashi,Yoshifumi Mori,Hideki Nakamoto,Keita Okada,Yuki Taniguchi,Shurei Sugita,Fumiko Yano,Ung-Il Chung,Joo-Ri Kim-Kaneyama,Motoko Yanagita,Aris Economides,Ernesto Canalis,Di Chen,Sakae Tanaka,Taku Saito

PloS one 12:e0180615 PubMed28686688

2017

Therapeutic impact of dietary vitamin D supplementation for preventing right ventricular remodeling and improving survival in pulmonary hypertension.

Applications

Unspecified application

Species

Rat

Hiroaki Tanaka,Masaharu Kataoka,Sarasa Isobe,Tsunehisa Yamamoto,Kohsuke Shirakawa,Jin Endo,Toru Satoh,Yoji Hakamata,Eiji Kobayashi,Motoaki Sano,Keiichi Fukuda
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com